Increased expression of TBX2 is a novel independent prognostic biomarker of a worse outcome in colorectal cancer patients after curative surgery and a potential therapeutic target

Han, Yang; Tu, Wei-Wei; Wen, Yu-Gang; Yan, Dong-Wang; Qiu, Guo-Qiang; Peng, Zhi-Hai; Zhou, Chong-Zhi
December 2013
Medical Oncology;Dec2013, Vol. 30 Issue 4, p1
Academic Journal
No abstract available.


Related Articles

  • Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation. Ching-Yih Lin; Yu-Feng Tian; Li-Ching Wu; Li-Tzong Chen; Li-Ching Lin; Chung-Hsi Hsing; Sung-Wei Lee; Ming-Jen Sheu; Hao-Hsien Lee; Yu-Hui Wang; Yow-Ling Shiue; Wen-Ren Wu; Hsuan-Ying Huang; Han-Ping Hsu; Chien-Feng Li; Shang-Hung Chen // Journal of Clinical Pathology;Aug2012, Vol. 65 Issue 8, p687 

    Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates...

  • Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. D'Angelica, Michael; Ammori, John; Gonen, Mithat; Klimstra, David S; Low, Philip S; Murphy, Linda; Weiser, Martin R; Paty, Philip B; Fong, Yuman; DeMatteo, Ronald P; Allen, Peter; Jarnagin, William R; Shia, Jinru // Modern Pathology;Sep2011, Vol. 24 Issue 9, p1221 

    No abstract available.

  • SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. Tian, Yu-Feng; Chen, Tzu-Ju; Lin, Ching-Yih; Chen, Li-Tzong; Lin, Li-Ching; Hsing, Chung-Hsi; Lee, Sung-Wei; Sheu, Ming-Jen; Lee, Hao-Hsien; Shiue, Yow-Ling; Huang, Hsuan-Ying; Pan, Hsin-Yi; Li, Chien-Feng; Chen, Shang-Hung // Tumor Biology;Apr2013, Vol. 34 Issue 2, p1107 

    The S-phase kinase-associated protein 2 (SKP2) oncoprotein is an E3 ubiquitin ligase. Overexpression of SKP2 was found in various human cancers, including colorectal cancers, but its potential role as a prognostic marker after neoadjuvant chemoradiotherapy (CRT) and for therapeutic intervention...

  • miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Yanlei Ma; Peng Zhang; Feng Wang; Huizhen Zhang; Jianjun Yang; Jiayuan Peng; Weijie Liu; Huanlong Qin // Gut;Oct2012, Vol. 61 Issue 10, p1447 

    Background MicroRNAs (miRNA) have potential as prognostic biomarkers and therapeutic targets in cancer. A study was undertaken to investigate the association between miRNA expression patterns and the prognosis and therapeutic outcome of colorectal cancer (CRC). Methods miRNA expression profiling...

  • ANGIOGENESIS-BASED PROGNOSTIC MARKERS IN IMMUNOHISTOCHEMISTRY FOR COLORECTAL CANCER PATIENTS. Ciocâlteu, Adriana; Săftoiu, Adrian; Pirici, Daniel; Cristea, Cosmin; Georgescu, Claudia-Valentina // Internal Medicine / Medicina Interna;2015, Vol. 12 Issue 4, p19 

    Angiogenesis plays a key role in the development and dissemination of colorectal cancer. In advanced stages this malignancy has a poor prognosis due to the inefficacy of the existent treatment and at this point the outcome cannot be completely predicted by common prognostic factors such as lymph...

  • Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer. Lhoumeau, Anne-Catherine; Martinez, Sébastien; Boher, Jean-Marie; Monges, Geneviève; Castellano, Rémy; Goubard, Armelle; Doremus, Marie; Poizat, Flora; Lelong, Bernard; de Chaisemartin, Cécile; Bardin, Florence; Viens, Patrice; Raoul, Jean-Luc; Prebet, Thomas; Aurrand-Lions, Michel; Borg, Jean-Paul; Gonçalves, Anthony // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Biomarkers and novel therapeutic targets are urgently needed in colorectal cancer (CRC). The pseudo tyrosine kinase receptor 7 (PTK7) is involved in planar cell polarity and it is deregulated in various malignancies, including CRC. Yet, little is known about its protein expression in human CRC,...

  • Identification of Clinically Relevant Molecular Subtypes in Colorectal Cancer: The Dawning of a New Era. Johnston, Patrick G. // Oncologist;2014, Vol. 19 Issue 5, p568 

    In recent years, a number of protein and genomic-based biomarkers have begun to refine the prognostic information available for colorectal cancer (CRC) and predict defined patient groups that are likely to benefit from systemic treatment or targeted therapies. Of these, KRAS represents the first...

  • High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma. Long, Qilai; Liu, Li; Xia, Yu; Bai, Qi; Wang, Jiajun; Xu, Jiejie; Guo, Jianming // Tumor Biology;Sep2015, Vol. 36 Issue 10, p8007 

    B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) is a transcriptional repressor, which plays important roles in the development of cancers, but the function of Bmi-1 in kidney tumorigenesis and its prognostic values remain unclear. This study aims to investigate prognostic values of the...

  • Mucinous Adenocarcinomas Histotype Can Also be a High-Risk Factor for Stage II Colorectal Cancer Patients. Xiang Hu; Ya-Qi Li; Qing-Guo Li; Yan-Lei Ma; Jun-Jie Peng; San-Jun Cai // Cellular Physiology & Biochemistry (Karger AG);Jun2018, Vol. 47 Issue 2, p630 

    Background/Aims: Colorectal mucinous adenocarcinoma (MA) has been associated with a worse prognosis than adenocarcinoma (AD) in advanced stages. Little is known about the prognostic impact of a mucinous histotype on the early stages of colorectal cancer with negative lymph node (LN) metastasis....

  • B-cell lymphoma 2 and β-catenin expression in colorectal cancer and their prognostic role following surgery. BALZI, MANUELA; RINGRESSI, MARIA NOVELLA; FARAONI, PAOLA; BOOTH, CATHERINE; TADDEI, ANTONIO; BONI, LUCA; BECHI, PAOLO // Molecular Medicine Reports;2015, Vol. 12 Issue 1, p553 

    The prognosis of colorectal cancer depends on the stage of the disease. However, even within the same stage there may be different outcomes in terms of recurrence and survival. Therefore, it is clear that as well as pathological stage, novel biomarkers that are capable of improving risk...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics